Bionomics Limited : BNC105 RENAL CANCER TRIAL DATA PRESENTED AT ASCO-GU 4-traders (press release) Bionomics is conducting a US multi-centre Phase II clinical trial of BNC105 in combination with everolimus (Afinitor) in patients with metastatic Renal Cell Carcinoma (RCC). Afinitor is an mTOR inhibitor, which is used as a treatment after patients ... |
